Literature DB >> 10327154

Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease.

M C Boll1, J Sotelo, E Otero, M Alcaraz-Zubeldia, C Rios.   

Abstract

Recent evidence suggest the implication of transition metals leading to overproduction of free radicals as a possible causal factor in the death of nigral cells associated to Parkinson's disease (PD). Iron depots in the basal ganglia of PD patients have been described; in addition, contents of nigral copper have been found decreased, while its concentration in cerebrospinal fluid (CSF) is raised, particularly the free form of the metal. To search for a possible link between altered copper concentrations and PD, we advanced the hypothesis that ferroxidase activity of ceruloplasmin is decreased in the CSF of PD patients. We studied 35 untreated PD patients, 14 L-3,4-dihydroxyphenylalanine (L-DOPA)-treated PD patients and 26 controls. Both CSF ferroxidase activity and CSF copper content were measured and correlated with the clinical stage of the disease. We found that untreated PD patients had a significant reduction of 40% in CSF ferroxidase while CSF copper was slightly increased as compared with both the values in L-DOPA-treated PD patients and controls. We also found that the fraction of copper linked to ferroxidase in untreated PD is inversely related to the clinical stage of the disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10327154     DOI: 10.1016/s0304-3940(99)00221-9

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  30 in total

1.  Neuroprotective effect of acute and chronic administration of copper (II) sulfate against MPP+ neurotoxicity in mice.

Authors:  M Alcaraz-Zubeldia; P Rojas; C Boll; C Rios
Journal:  Neurochem Res       Date:  2001-01       Impact factor: 3.996

2.  Plasma ceruloplasmin ferroxidase activity correlates with the nigral sonographic area in Parkinson's disease patients: a pilot study.

Authors:  Rubén Martínez-Hernández; Sergio Montes; Jesus Higuera-Calleja; Petra Yescas; Marie-Catherine Boll; Araceli Diaz-Ruiz; Camilo Rios
Journal:  Neurochem Res       Date:  2011-06-26       Impact factor: 3.996

Review 3.  The role of iron in brain ageing and neurodegenerative disorders.

Authors:  Roberta J Ward; Fabio A Zucca; Jeff H Duyn; Robert R Crichton; Luigi Zecca
Journal:  Lancet Neurol       Date:  2014-10       Impact factor: 44.182

4.  Single-nucleotide polymorphisms and haplotypes of non-coding area in the CP gene are correlated with Parkinson's disease.

Authors:  Na Zhao; Jianqiu Xiao; Zhiyong Zheng; Guoqiang Fei; Feng Zhang; Lirong Jin; Chunjiu Zhong
Journal:  Neurosci Bull       Date:  2015-03-10       Impact factor: 5.203

5.  The Ferroxidase Hephaestin But Not Amyloid Precursor Protein is Required for Ferroportin-Supported Iron Efflux in Primary Hippocampal Neurons.

Authors:  Changyi Ji; Brittany L Steimle; Danielle K Bailey; Daniel J Kosman
Journal:  Cell Mol Neurobiol       Date:  2017-11-25       Impact factor: 5.046

6.  Iron in neurodegenerative disorders.

Authors:  D. Berg; G. Becker; P. Riederer; O. Riess
Journal:  Neurotox Res       Date:  2002 Nov-Dec       Impact factor: 3.911

Review 7.  Ceruloplasmin and what it might do.

Authors:  J Healy; K Tipton
Journal:  J Neural Transm (Vienna)       Date:  2007-04-04       Impact factor: 3.575

8.  A low-molecular-weight ferroxidase is increased in the CSF of sCJD cases: CSF ferroxidase and transferrin as diagnostic biomarkers for sCJD.

Authors:  Swati Haldar; 'alim J Beveridge; Joseph Wong; Ajay Singh; Daniela Galimberti; Barbara Borroni; Xiongwei Zhu; Janis Blevins; Justin Greenlee; George Perry; Chinmay K Mukhopadhyay; Christine Schmotzer; Neena Singh
Journal:  Antioxid Redox Signal       Date:  2013-04-16       Impact factor: 8.401

Review 9.  Brain Iron Metabolism Dysfunction in Parkinson's Disease.

Authors:  Hong Jiang; Jun Wang; Jack Rogers; Junxia Xie
Journal:  Mol Neurobiol       Date:  2016-04-02       Impact factor: 5.590

10.  Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF. A different marker profile in four neurodegenerative diseases.

Authors:  Marie-Catherine Boll; Mireya Alcaraz-Zubeldia; Sergio Montes; Camilo Rios
Journal:  Neurochem Res       Date:  2008-02-29       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.